Canada’s Bausch to pay $300 million in antitrust settlement; Cardiff releases data on mCRC trial

Canadian pharma company Bausch Health has agreed to settle an antitrust class-action suit from a 2015 price increase.

According to Reuters, the class-action lawsuit accused Bausch of maintaining an illegal monopoly on diabetes drug Glumetza, enabling a price hike of nearly 800% in 2015 from $5.72...

Click to view original post